Scotia Capital Inc. Point Biopharma Global Inc. Transaction History

Scotia Capital Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 03, 2023	SELL	$6.86 - $10.86 $2.23 Million - $3.53 Million	-325,000 Reduced 86.67%	50,000 $453,000
Q3 2022 Nov 10, 2022	SELL	$7.24 - $10.31 $165,506 - $235,686	-22,860 Reduced 5.75%	375,000 $2.9 Million
Q2 2022 Aug 05, 2022	BUY	$5.6 - $9.5 $1.1 Million - $1.86 Million	196,229 Added 97.32%	397,860 $2.71 Million
Q1 2022 May 09, 2022	BUY	$5.46 - $8.13 $1.1 Million - $1.64 Million	201,631 New	201,631 $1.61 Million

20K

Ticker PNT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 104,025,000
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...

Get notified when there are updates to the investment portfolio of Scotia Capital Inc., based on Form 13F filings with the SEC.

Stay updated on Scotia Capital Inc. with notifications on news.